SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN)
Clinical trials for SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN) explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN) trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental cancer drug trial halted after early testing
Disease control TerminatedThis study tested a new drug called TAK-500, alone or with pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The goal was to check safety and see if the drug could shrink tumors. The trial was terminated early, so results are limited.
Matched conditions: SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN)
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New cancer drug trial halted early after testing in 95 patients
Disease control TerminatedThis study tested a new drug called TAK-186 in adults with advanced head and neck, lung, or colorectal cancer that could not be removed by surgery. The main goal was to check for side effects and find the best dose. The trial was stopped early, and 95 people took part.
Matched conditions: SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN)
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 03:55 UTC